1519 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma

Page last updated: 18 April 2019

Application Detail



Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 chimeric antigen receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Acute lymphoblastic leukaemia (ALL) is the malignant proliferation of lymphoid progenitor cells in the bone marrow.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin lymphoma (NHL).

Reason for Application

New non-MBS item

Medical Service Type

Hybrid health technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 842 KB)
Application Form (Word 498 KB)

PICO Confirmation

PICO Confirmation (PDF 1458 KB)
PICO Confirmation (Word 743 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 1116 KB)
Public Summary Document (Word 126 KB)

Meetings for this Application


12-13 April 2018


5 October 2018


22-23 November 2018
28-29 March 2019
9 April 2019